Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency

Production Increase:
Bavarian Nordic announced plans to increase production of its mpox vaccine, Jynneos, in response to the ongoing outbreak in Africa and potential spread to other continents.

Supply Capacity:
The company can deliver up to 2 million additional vaccine doses by the end of 2024 and has the capacity to expand to 10 million doses by the end of 2025.

Partnerships:
Bavarian Nordic is working closely with the Africa Centers for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) to ensure equitable access to the vaccine.

Clinical Data:
The company has generated clinical data to support the use of Jynneos in younger patients aged 12 to 17 years and is preparing to launch a study to assess the vaccine in individuals two to 12 years of age.

Global Response:
The WHO declared the current mpox outbreak a public health emergency, prompting several agencies to purchase doses from Bavarian Nordic to help manage the situation in Africa.

Financial Impact:
Analysts suggest that the mpox outbreak could result in significant revenue for Bavarian Nordic, potentially up to $600 million to $1 billion in 2025.